Erratum to: Cost Effectiveness of Tiotropium in Patients with Asthma Poorly Controlled on Inhaled Glucocorticosteroids and Long-Acting β-Agonists (Applied Health Economics and Health Policy, 12:447-459, (2014), DOI 10.1007/s40258-014-0107-8);Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting β-agonists

Applied Health Economics and Health Policy

Volumn 12, Issue 4, 2014, Pages 447-459

  Willson, Jenny ^a   Bateman, Eric D ^b   Pavord, Ian ^c   Lloyd, Adam ^a   Krivasi, Tania ^a   Esser, Dirk ^d  

^a IQVIA   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; GLUCOCORTICOID; PLACEBO; RESPIMAT; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; BRONCHODILATING AGENT; DELAYED RELEASE FORMULATION; SCOPOLAMINE DERIVATIVE;

ADD ON THERAPY; ADOLESCENT; ADULT; ARTICLE; ASTHMA; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG MEGADOSE; HEALTH STATUS; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; METERED DOSE INHALER; MORTALITY; OUTCOME ASSESSMENT; PARALLEL DESIGN; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SOFT MIST INHALER; TREATMENT DURATION; ADMINISTRATION AND DOSAGE; ARTIFICIAL VENTILATION; COST BENEFIT ANALYSIS; DELAYED RELEASE FORMULATION; ECONOMICS; PROBABILITY; TREATMENT OUTCOME;

ADRENERGIC BETA-AGONISTS; ASTHMA; BRONCHODILATOR AGENTS; COST-BENEFIT ANALYSIS; DELAYED-ACTION PREPARATIONS; HUMANS; MARKOV CHAINS; QUALITY-ADJUSTED LIFE YEARS; RESPIRATORY THERAPY; SCOPOLAMINE DERIVATIVES; TIOTROPIUM BROMIDE; TREATMENT OUTCOME;

EID: 84905116260     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-015-0216-z     Document Type: Erratum

References (29)

1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention (2012 update). GINA; 2013. http://www.ginasthma.org. Accessed Sep 2013.
2. British Thoracic Society (BTS), Scottish Intercollegiate Guidelines Network (SIGN). British guideline on the management of asthma; a national clinical guideline. BTS/SIGN; 2012. http://www.sign.ac.uk/pdf/sign101.pdf. Accessed Sep 2013.
3. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention (2007 update). GINA; 2007. http://www.ginasthma.org. Accessed Sep 2013.
4. Antonicelli L, Bucca C, Neri M, De BF, Sabbatani P, Bonifazi F, et al. Asthma severity and medical resource utilisation. Eur Respir J. 2004;23(5):723-9. (Pubitemid 38618143)
5. Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J. 2002;19(1):61-7. (Pubitemid 34105569)
6. Van GE, Laforest L, Pietri G, Boissel JP, Gormand F, Ben-Joseph R, et al. Persistent asthma: disease control, resource utilisation and direct costs. Eur Respir J. 2002;20(2):260-7.
7. Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367(13):1198-207.
8. Briggs AH, Ades AE, Price MJ. Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework. Med Decis Making. 2003;23(4):341-50. (Pubitemid 36899100)
9. Office of National Statistics. United Kingdom, interim life tables 2008-2010. ONS; 2012. http://www.ons.gov.uk/ons/publications/re-reference- tables.html?edition=tcm%3A77-223324. Accessed Jul 2012.
10. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095-108. (Pubitemid 127453463)
11. Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J. 2007;16(1):22-7. (Pubitemid 46364352)
12. Gerzeli S, Rognoni C, Quaglini S, Cavallo MC, Cremonesi G, Papi A. Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma. Clin Drug Investig. 2012;32(4):253-65.
13. Price D, Berg J, Lindgren P. An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom. Allergy. 2009;64(3):431-8.
14. Steuten L, Palmer S, Vrijhoef B, van Merode F, Spreeuwenberg C, Severens H. Cost-utility of a disease management program for patients with asthma. Int J Technol Assess Health Care. 2007;23:184-91. (Pubitemid 46642726)
15. Personal Social Services Research Unit (PSSRU). Unit costs of health and social care 2012. PSSRU; 2013. http://www.pssru.ac.uk/project-pages/unit-costs/ 2012/. Accessed Apr 2013.
16. Department of Health. NHS Trust and PCTs combined reference cost schedules 2011-2012. Department of Health; 2013. http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH-131140. Accessed Apr 2013.
17. Joint Formulary Committee. British National Formulary 65 (online ed.). BNF; 2013. http://www.bnf.org. Accessed Apr 2013.
18. National Institute for Health and Clinical Excellence. Omalizumab for severe persistent allergic asthma. A single technology appraisal. NICE; 2007. http://www.nice.org.uk/nicemedia/pdf/TA133Guidance.pdf. Accessed Jul 2012.
19. Watson L, Turk F, James P, Holgate ST. Factors associated with mortality after an asthma admission: a national United Kingdom database analysis. Respir Med. 2007;101(8):1659-64. (Pubitemid 46947879)
20. Dewilde S, Turk F, Tambour M, Sandstrom T. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin. 2006;22(9):1765-76. (Pubitemid 44449233)
21. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. NICE; 2008. http://www.nice.org.uk/media/B52/ A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed Apr 2012.
22. Price MJ, Briggs AH. Development of an economic model to assess the cost effectiveness of asthma management strategies. Pharmacoeconomics. 2002;20(3):183-94. (Pubitemid 34454643)
23. Paltiel AD, Fuhlbrigge AL, Kitch BT, Liljas B, Weiss ST, Neumann PJ, et al. Cost effectiveness of inhaled corticosteroids in adults with mild to moderate asthma: results from the asthma policy model. J Allergy Clin Immunol. 2001;108(1):39-46. (Pubitemid 32662230)
24. Wu AC, Paltiel AD, Kuntz KM, Weiss ST. Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol. 2007;120(5):1146-52. (Pubitemid 350029901)
25. ISPOR. Pharmacoeconomic guidelines around the world. ISPOR; 2007. http://www.ispor.org/PEguidelines/index.asp. Accessed Sep 2007.
26. Guyatt GH, King DR, Feeny DH, Stubbing D, Goldstein RS. Generic and specific measurement of health-related quality of life in a clinical trial of respiratory rehabilitation. J Clin Epidemiol. 1999;52(3):187-92. (Pubitemid 29148429)
27. Puhan MA, Guyatt GH, Goldstein R, Mador J, McKim D, Stahl E, et al. Relative responsiveness of the Chronic Respiratory Questionnaire, St. Georges Respiratory Questionnaire and four other health-related quality of life instruments for patients with chronic lung disease. Respir Med. 2007;101(2):308-16. (Pubitemid 46075963)
28. Martínez-Moragón E, Serra-Batllés J, De Diego A, Palop M, Casan P, Rubio-Terrés C. Economic cost of treating the patient with asthma in Spain: the AsmaCost study. Arch Bronconeumol. 2009;45(10):481-6.
29. Lane S, Molina J, Plusa T. An international observational prospective study to determine the cost of asthma exacerbations (COAX). Respir Med. 2006;100(3):434-50. (Pubitemid 43239877)